Samsung Biologics Expands South Korean Footprint

---

Researched by Industrial Info Resources (Sugar Land, Texas)--Samsung Biologics (Incheon, South Korea) will begin work on a second biocampus in South Korea with the construction of "Plant 5," which will be built in Songdo District 11, Incheon.

Samsung Biologics is preemptively responding to the growing demand for biopharmaceutical contract development and management organizations (CDMOs) while securing competitiveness in global production capacity. Amid the increasing outsourcing of biopharmaceutical production after COVID-19, Samsung Biologics is actively making preemptive investments to continue to dominate the market.

Construction on Plant 5 is planned to begin this summer and be completed in 2026. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical-Biotech Database can click here for the project report.

Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 trillion (USD).